Rafarma Pharmaceuticals Profit Margin

Rafarma Pharmaceuticals (RAFA) currently reports a profit margin of 4.22% as of September 2026. That compares with 3.35% in the prior-year period — up 25.9% year over year. That is below the sector sector average of 13.78%. Use the charts on this page to explore Rafarma Pharmaceuticals's profit margin history and peer comparisons.

Rafarma Pharmaceuticals's profit margin increased from 3.35% to 4.22% — a 25.9% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Rafarma Pharmaceuticals's profit margin of 4.22% is lower than the its sector sector average of 13.78%. That is roughly 69.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Rafarma Pharmaceuticals's current 4.22% should be judged against industry norms (sector average: 13.78%) and against RAFA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 4.22%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 13.78%. From there, open related valuation or income-statement pages for Rafarma Pharmaceuticals, and consider following RAFA for alerts when major investors trade the stock.